Anavex Life Sciences has been granted a patent for a method using AV1066 to treat pain, specifically targeting visceral and neuropathic pain. The patent claims a dosage form of AV1066 in the (+) form to relieve or prevent pain in subjects. GlobalData’s report on Anavex Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Anavex Life Sciences, Cancer treatment biomarkers was a key innovation area identified from patents. Anavex Life Sciences's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment/prevention of pain using av1066 dosage form
A recently granted patent (Publication Number: US11896590B2) discloses a dosage form containing a therapeutically effective amount of 1-(3-(4(((1R, 3S, 5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine (“AV1066”) or a pharmaceutically acceptable salt thereof. The purpose of this dosage form is to relieve or prevent pain in individuals experiencing pain-related conditions. The formulation specifically includes AV1066 in the (+) form while being substantially absent of the (-) form, ensuring its efficacy in pain management.
The patent further details the various applications of this dosage form, including the relief of nociceptive pain, visceral pain, neuropathic pain, and hyperalgesia. It specifies that the pain targeted could stem from conditions such as fractures, burns, obstructions, postherpetic pain, or trigeminal neuralgia. The dosage form can be administered orally, through inhalation, subcutaneously, or parenterally, with dosing frequencies ranging from once to three times a day. Additionally, the patent mentions the possibility of intermittent or continuous administration over a period of 1 to 4 weeks, with the therapeutically effective amount falling within the range of 5 mg/kg/day to 30 mg/kg/day. The patent also covers scenarios where the subject may have undergone or is currently undergoing other analgesic treatments, including NSAIDs, and the potential inclusion of a second analgesic in the formulation.
To know more about GlobalData’s detailed insights on Anavex Life Sciences, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
